Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures

systematic review and meta-analysis

Taichi Saitou, J. M. Sterbenz, S. Malay, L. Zhong, M. P. MacEachern, K. C. Chung

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Patients with osteoporotic fractures have an increased risk for secondary fractures. However, a rigorous study that assesses the effectiveness of individual osteoporotic drugs in preventing subsequent fractures is lacking. The purpose of this review was to analyze the effectiveness of anti-osteoporotic drugs in preventing secondary fractures. We searched for randomized controlled trials that showed the incidence of secondary fractures while using anti-osteoporotic drugs (bisphosphonates, selective estrogen receptor modulators, parathyroid hormone (PTH), or calcitonin) in MEDLINE, Embase.com, and Cochrane Central Register databases. We estimated risk ratios (RR) and numbers needed to treat (NNT) to prevent secondary fractures. Twenty-six studies met our eligibility criteria. There was a significant reduction in RR (0.38–0.77) after the use of anti-osteoporotic drugs for secondary vertebral fractures. Bisphosphonates and PTH significantly reduced the risk of a secondary non-vertebral fracture (RR 0.59 and 0.64). PTH needed the fewest number of patients to be treated to prevent a secondary vertebral fracture (NNT: 56). Our study demonstrated the effectiveness of anti-osteoporotic agents included in our systematic review in preventing secondary vertebral fractures. Bisphosphonates and PTH were most effective in preventing non-vertebral fractures. We suggest that clinicians should prescribe these drugs to prevent secondary vertebral/non-vertebral fractures.

Original languageEnglish
Pages (from-to)3289-3300
Number of pages12
JournalOsteoporosis International
Volume28
Issue number12
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Meta-Analysis
Parathyroid Hormone
Diphosphonates
Numbers Needed To Treat
Pharmaceutical Preparations
Odds Ratio
Selective Estrogen Receptor Modulators
Osteoporotic Fractures
Calcitonin
MEDLINE
Randomized Controlled Trials
Databases
Incidence

Keywords

  • Bisphosphonates
  • Drug therapy
  • Fragility fracture
  • Osteoporosis
  • Parathyroid hormone
  • Secondary fractures
  • Selective estrogen receptor modulators

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures : systematic review and meta-analysis. / Saitou, Taichi; Sterbenz, J. M.; Malay, S.; Zhong, L.; MacEachern, M. P.; Chung, K. C.

In: Osteoporosis International, Vol. 28, No. 12, 01.12.2017, p. 3289-3300.

Research output: Contribution to journalReview article

Saitou, Taichi ; Sterbenz, J. M. ; Malay, S. ; Zhong, L. ; MacEachern, M. P. ; Chung, K. C. / Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures : systematic review and meta-analysis. In: Osteoporosis International. 2017 ; Vol. 28, No. 12. pp. 3289-3300.
@article{21dbcebd9e794c6484eaa813d570c78c,
title = "Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis",
abstract = "Patients with osteoporotic fractures have an increased risk for secondary fractures. However, a rigorous study that assesses the effectiveness of individual osteoporotic drugs in preventing subsequent fractures is lacking. The purpose of this review was to analyze the effectiveness of anti-osteoporotic drugs in preventing secondary fractures. We searched for randomized controlled trials that showed the incidence of secondary fractures while using anti-osteoporotic drugs (bisphosphonates, selective estrogen receptor modulators, parathyroid hormone (PTH), or calcitonin) in MEDLINE, Embase.com, and Cochrane Central Register databases. We estimated risk ratios (RR) and numbers needed to treat (NNT) to prevent secondary fractures. Twenty-six studies met our eligibility criteria. There was a significant reduction in RR (0.38–0.77) after the use of anti-osteoporotic drugs for secondary vertebral fractures. Bisphosphonates and PTH significantly reduced the risk of a secondary non-vertebral fracture (RR 0.59 and 0.64). PTH needed the fewest number of patients to be treated to prevent a secondary vertebral fracture (NNT: 56). Our study demonstrated the effectiveness of anti-osteoporotic agents included in our systematic review in preventing secondary vertebral fractures. Bisphosphonates and PTH were most effective in preventing non-vertebral fractures. We suggest that clinicians should prescribe these drugs to prevent secondary vertebral/non-vertebral fractures.",
keywords = "Bisphosphonates, Drug therapy, Fragility fracture, Osteoporosis, Parathyroid hormone, Secondary fractures, Selective estrogen receptor modulators",
author = "Taichi Saitou and Sterbenz, {J. M.} and S. Malay and L. Zhong and MacEachern, {M. P.} and Chung, {K. C.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s00198-017-4175-0",
language = "English",
volume = "28",
pages = "3289--3300",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "12",

}

TY - JOUR

T1 - Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures

T2 - systematic review and meta-analysis

AU - Saitou, Taichi

AU - Sterbenz, J. M.

AU - Malay, S.

AU - Zhong, L.

AU - MacEachern, M. P.

AU - Chung, K. C.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Patients with osteoporotic fractures have an increased risk for secondary fractures. However, a rigorous study that assesses the effectiveness of individual osteoporotic drugs in preventing subsequent fractures is lacking. The purpose of this review was to analyze the effectiveness of anti-osteoporotic drugs in preventing secondary fractures. We searched for randomized controlled trials that showed the incidence of secondary fractures while using anti-osteoporotic drugs (bisphosphonates, selective estrogen receptor modulators, parathyroid hormone (PTH), or calcitonin) in MEDLINE, Embase.com, and Cochrane Central Register databases. We estimated risk ratios (RR) and numbers needed to treat (NNT) to prevent secondary fractures. Twenty-six studies met our eligibility criteria. There was a significant reduction in RR (0.38–0.77) after the use of anti-osteoporotic drugs for secondary vertebral fractures. Bisphosphonates and PTH significantly reduced the risk of a secondary non-vertebral fracture (RR 0.59 and 0.64). PTH needed the fewest number of patients to be treated to prevent a secondary vertebral fracture (NNT: 56). Our study demonstrated the effectiveness of anti-osteoporotic agents included in our systematic review in preventing secondary vertebral fractures. Bisphosphonates and PTH were most effective in preventing non-vertebral fractures. We suggest that clinicians should prescribe these drugs to prevent secondary vertebral/non-vertebral fractures.

AB - Patients with osteoporotic fractures have an increased risk for secondary fractures. However, a rigorous study that assesses the effectiveness of individual osteoporotic drugs in preventing subsequent fractures is lacking. The purpose of this review was to analyze the effectiveness of anti-osteoporotic drugs in preventing secondary fractures. We searched for randomized controlled trials that showed the incidence of secondary fractures while using anti-osteoporotic drugs (bisphosphonates, selective estrogen receptor modulators, parathyroid hormone (PTH), or calcitonin) in MEDLINE, Embase.com, and Cochrane Central Register databases. We estimated risk ratios (RR) and numbers needed to treat (NNT) to prevent secondary fractures. Twenty-six studies met our eligibility criteria. There was a significant reduction in RR (0.38–0.77) after the use of anti-osteoporotic drugs for secondary vertebral fractures. Bisphosphonates and PTH significantly reduced the risk of a secondary non-vertebral fracture (RR 0.59 and 0.64). PTH needed the fewest number of patients to be treated to prevent a secondary vertebral fracture (NNT: 56). Our study demonstrated the effectiveness of anti-osteoporotic agents included in our systematic review in preventing secondary vertebral fractures. Bisphosphonates and PTH were most effective in preventing non-vertebral fractures. We suggest that clinicians should prescribe these drugs to prevent secondary vertebral/non-vertebral fractures.

KW - Bisphosphonates

KW - Drug therapy

KW - Fragility fracture

KW - Osteoporosis

KW - Parathyroid hormone

KW - Secondary fractures

KW - Selective estrogen receptor modulators

UR - http://www.scopus.com/inward/record.url?scp=85026741332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026741332&partnerID=8YFLogxK

U2 - 10.1007/s00198-017-4175-0

DO - 10.1007/s00198-017-4175-0

M3 - Review article

VL - 28

SP - 3289

EP - 3300

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 12

ER -